Drug intelligence / Profile preview

HBW-011

Development stage: Unknown
Lead developer: Hyperway Pharmaceutical
Modality: Small Molecules

Overview

HBW-011 is a small molecule antifungal candidate developed by Hyperway Pharmaceutical (also known as Chengdu Haibowei Pharmaceutical). It is being developed for the treatment of various fungal infections (mycoses). According to company pipeline information, the drug has completed five Phase 1 clinical trials and is currently in Phase 1/2 development. In 2024, Hyperway Pharmaceutical entered into a development partnership for HBW-011 with an undisclosed external organization. While the drug is a key part of Hyperway's infectious disease portfolio, its specific biological target and molecular mechanism of action have not yet been publicly disclosed.

Beyond the preview

Go deeper on HBW-011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HBW-011.

Explore the full profile